SHYNDEC(SH:600420) Xin Lang Cai Jing·2025-09-01 09:24Core Viewpoint - The approval of injectable Nicorandil by the National Medical Products Administration enhances the company's product offerings in the cardiovascular field and strengthens its market competitiveness in related medications [1] Group 1: Product Approval - The company's wholly-owned subsidiary, China National Pharmaceutical Group Modern, has received approval for injectable Nicorandil [1] - The drug is primarily used for the treatment of unstable angina pectoris [1] Group 2: Market Potential - According to the MiNei database, the projected sales for injectable Nicorandil in public medical institutions nationwide is 624 million yuan in 2024 [1] - The cumulative R&D investment for this project by the company is approximately 4.182 million yuan [1] Group 3: Competitive Advantage - The approval of this drug will enrich the company's cardiovascular formulation products [1] - This development is expected to enhance the company's competitiveness in the relevant medication market [1]